Oscotec Inc.

Translating science into medicine
Sign Up
  1. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

    Read More
  2. YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results

    Read More
  3. YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

    Read More
  4. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

    Read More
  5. YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

    Read More
  6. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

    Read More
  7. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

    Read More
  8. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

    Read More
  9. Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode

    Read More
Board Pagination Prev 1 Next
/ 1
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.